These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

662 related items for PubMed ID: 27996251

  • 1. Introducing the 4-Phenyl-1,2,3-Triazole Moiety as a Versatile Scaffold for the Development of Cytotoxic Ruthenium(II) and Osmium(II) Arene Cyclometalates.
    Riedl CA, Flocke LS, Hejl M, Roller A, Klose MH, Jakupec MA, Kandioller W, Keppler BK.
    Inorg Chem; 2017 Jan 03; 56(1):528-541. PubMed ID: 27996251
    [Abstract] [Full Text] [Related]

  • 2. Piano-Stool Ruthenium(II) Complexes with Delayed Cytotoxic Activity: Origin of the Lag Time.
    Rafols L, Josa D, Aguilà D, Barrios LA, Roubeau O, Cirera J, Soto-Cerrato V, Pérez-Tomás R, Martínez M, Grabulosa A, Gamez P.
    Inorg Chem; 2021 Jun 07; 60(11):7974-7990. PubMed ID: 33979132
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Synthesis, structure and anticancer properties of new biotin- and morpholine-functionalized ruthenium and osmium half-sandwich complexes.
    Marloye M, Inam H, Moore CJ, Debaille V, Pritchard JR, Gelbcke M, Meyer F, Dufrasne F, Berger G.
    J Biol Inorg Chem; 2021 Aug 07; 26(5):535-549. PubMed ID: 34173882
    [Abstract] [Full Text] [Related]

  • 7. Identification of the structural determinants for anticancer activity of a ruthenium arene peptide conjugate.
    Meier SM, Novak M, Kandioller W, Jakupec MA, Arion VB, Metzler-Nolte N, Keppler BK, Hartinger CG.
    Chemistry; 2013 Jul 08; 19(28):9297-307. PubMed ID: 23712572
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Novel C,N-Cyclometalated Benzimidazole Ruthenium(II) and Iridium(III) Complexes as Antitumor and Antiangiogenic Agents: A Structure-Activity Relationship Study.
    Yellol J, Pérez SA, Buceta A, Yellol G, Donaire A, Szumlas P, Bednarski PJ, Makhloufi G, Janiak C, Espinosa A, Ruiz J.
    J Med Chem; 2015 Sep 24; 58(18):7310-27. PubMed ID: 26313136
    [Abstract] [Full Text] [Related]

  • 10. Half-Sandwich Iridium(III) and Ruthenium(II) Complexes Containing P^P-Chelating Ligands: A New Class of Potent Anticancer Agents with Unusual Redox Features.
    Li J, Tian M, Tian Z, Zhang S, Yan C, Shao C, Liu Z.
    Inorg Chem; 2018 Feb 19; 57(4):1705-1716. PubMed ID: 29400963
    [Abstract] [Full Text] [Related]

  • 11. Derivation of structure-activity relationships from the anticancer properties of ruthenium(II) arene complexes with 2-aryldiazole ligands.
    Martínez-Alonso M, Busto N, Jalón FA, Manzano BR, Leal JM, Rodríguez AM, García B, Espino G.
    Inorg Chem; 2014 Oct 20; 53(20):11274-88. PubMed ID: 25302401
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. A SAR study of novel antiproliferative ruthenium and osmium complexes with quinoxalinone ligands in human cancer cell lines.
    Ginzinger W, Mühlgassner G, Arion VB, Jakupec MA, Roller A, Galanski MS, Reithofer M, Berger W, Keppler BK.
    J Med Chem; 2012 Apr 12; 55(7):3398-413. PubMed ID: 22417128
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Ruthenium(II) and osmium(II) 1,2,3-triazolylidene organometallics: a preliminary investigation into the biological activity of 'click' carbene complexes.
    Kilpin KJ, Crot S, Riedel T, Kitchen JA, Dyson PJ.
    Dalton Trans; 2014 Jan 21; 43(3):1443-8. PubMed ID: 24201979
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Novel ciprofloxacin hybrids using biology oriented drug synthesis (BIODS) approach: Anticancer activity, effects on cell cycle profile, caspase-3 mediated apoptosis, topoisomerase II inhibition, and antibacterial activity.
    Kassab AE, Gedawy EM.
    Eur J Med Chem; 2018 Apr 25; 150():403-418. PubMed ID: 29547830
    [Abstract] [Full Text] [Related]

  • 19. Determination of in vitro absorption in Caco-2 monolayers of anticancer Ru(II)-based complexes acting as dual human topoisomerase and PARP inhibitors.
    de Camargo MS, De Grandis RA, da Silva MM, da Silva PB, Santoni MM, Eismann CE, Menegário AA, Cominetti MR, Zanelli CF, Pavan FR, Batista AA.
    Biometals; 2019 Feb 25; 32(1):89-100. PubMed ID: 30506342
    [Abstract] [Full Text] [Related]

  • 20. New organoruthenium compounds with pyrido[2',3':5,6]pyrazino[2,3-f][1, 10]phenanthroline: synthesis, characterization, cytotoxicity, and investigation of mechanism of action.
    Pavlović M, Nikolić S, Gligorijević N, Dojčinović B, Aranđelović S, Grgurić-Šipka S, Radulović S.
    J Biol Inorg Chem; 2019 Mar 25; 24(2):297-310. PubMed ID: 30762123
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 34.